Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 2
- Registration Number
- NCT02936206
- Locations
- 🇺🇸
Mount Sinai West, New York, New York, United States
🇺🇸Mount Sinai St. Luke's, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Shannon Puhalla
- Target Recruit Count
- 7
- Registration Number
- NCT02913430
- Locations
- 🇺🇸
Magee-Womens Hospital UPMC, Pittsburgh, Pennsylvania, United States
Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 5
- Registration Number
- NCT02911844
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Fulvestrant 500mg in Patients With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 500
- Registration Number
- NCT02909361
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 388
- Registration Number
- NCT02894398
- Locations
- 🇩🇪
Research Site, Wilhelmshaven, Germany
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 96
- Registration Number
- NCT02860000
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Fresenius Kabi
- Target Recruit Count
- 266
- Registration Number
- NCT02795039
- Locations
- 🇨🇦
BioPharma Services Inc., Toronto, Ontario, Canada
🇨🇦Algorithme Pharma Inc., Mount Royal, Quebec, Canada
🇨🇦Lambda Therapeutic Research Inc., Toronto, Ontario, Canada
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 52
- Registration Number
- NCT02792465
- Locations
- 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 47
- Registration Number
- NCT02778685
- Locations
- 🇺🇸
City of Hope Corona, Corona, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope Antelope Valley, Lancaster, California, United States
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 463
- Registration Number
- NCT02763566
- Locations
- 🇧🇷
Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil
🇨🇳Jilin Province Tumor Hospital, Chang Chun, Ji Lin, China
🇨🇳Liaoning Cancer Hospital&Institute, Shenyang, Liaoning, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.